Pyrrolopyrazine kinase inhibitors

A compound of Formula I

• wherein:
• R is H, cyano, lower alkyl, R′ or
• R′ is cycloalkyl, heterocycloalkyl, heteroaryl, or phenyl, wherein each is optionally substituted with one or more R″;
• each R″ is independently halo, hydroxy, cyano, lower alkyl, lower haloalkyl, lower alkoxy, lower hydroxyalkyl, cycloalkyl, C(═O)R′″, or S(═O)2R′″;
• each R′″ is independently OH or lower alkyl;
• R1a and R1b are each independently H, hydroxy, halo, lower alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, lower alkoxy, lower haloalkoxy, lower hydroxyalkyl, amino, lower alkylamino, lower dialkylamino, cyano, C(═O)R′″, S(═O)2R′″ or CH2S(═O)2R′″;
• R1c is phenyl, cycloalkyl, heterocycloalkyl, or heteroaryl, optionally substituted with one or more R1d;
• each R1d is independently hydroxy, halo, lower alkyl, lower hydroxyalkyl, lower halo alkyl, or lower alkoxy;
• R2 is H, hydroxy lower alkyl, lower haloalkyl, or lower alkyl;
• R3 is H, hydroxy, cyano, cyano lower alkyl, or R3′;
• each R3′ is independently lower alkyl, hydroxy lower alkyl, lower alkoxy, lower haloalkyl, lower haloalkoxy, phenyl lower alkyl, cycloalkyl or cycloalkyl lower alkyl, each optionally substituted with one or more R3″;
• each R3″ is independently lower alkyl, halo, hydroxy, lower alkoxy, lower haloalkyl, lower hydroxy alkyl, oxo, amino, cyano, cyano lower alkyl, S(═O)2R3′″, C(═O)R3′″, cycloalkyl, heterocycloalkyl, heteroaryl, or heterocycloalkenyl;
• each R3′″ is independently H, hydroxy or lower alkyl;
• Q is Q2;
• Q2 is optionally substituted with one or more Q2a;
• Q2a is Q2b or Q2c;
• each Q2b is independently halogen, oxo, hydroxy, —CN, —SCH3, —S(O)2CH3, or —S(═O)CH3;
• each Q2a is independently Q2d or Q2e;
• or two Q2a come together to form a bicyclic ring system, optionally substituted with one or more Q2b or Q2c;
• each Q2d is independently —O(Q2e), —S(═O)2(Q2e), —C(═O)N(Q2e)2, —S(O)2(Q2e), —C(═O)(Q2e), —C(═O)O(Q2e), —N(Q2e)C(═O)(Q2e), —N(Q2e)C(═O)O(Q2e), or —N(Q2e)C(═O)N(Q2e)2;
• each Q2e is independently H or Q2e′;
• each Q2e′ is independently lower alkyl, phenyl, benzyl, 5,6,7,8-Tetrahydro-naphthalene, lower haloalkyl, lower alkoxy, cycloalkyl, cycloalkenyl, heterocycloalkyl, spirocyclic heterocycloalkyl, or heteroaryl, optionally substituted with one or more Q2f;
• each Q2f is independently Q2g or Q2h;
• each Q2g is independently halogen, hydroxy, cyano, oxo, —S(═O)2(Q2i′), S(═O)2N(Q2i′)2, —C(═O)OH, C(═O)N(Q2i′)2, or —C(═O)(Q2i′);
• each Q2h is independently lower alkyl, lower alkenyl, lower haloalkyl, lower alkoxy, amino, phenyl, benzyl, cycloalkyl, heterocycloalkyl, or heteroaryl, optionally substituted with one or more Q2i;
• and
• each Q2i is independently halogen, hydroxy, cyano, lower alkyl, lower haloalkyl, or lower alkoxy;
• each Q2i′ is independently H or lower alkyl;
• with the proviso that the compound of Formula I is not 2-Thiophen-2-yl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide;
• 2-Thiophen-2-yl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-hydroxy-2,2-dimethyl-propyl)-amide;
• or compound with trifluoro-acetic acid;
• or a pharmaceutically acceptable salt thereof.